CRi, VisEn Ink Deal; CRi to Distribute VisEn's Labels in North America
Cambridge Research & Instrumentation and VisEn Medical announced this week that they have signed a non-exclusive agreement that allows CRi to distribute VisEn's proprietary portfolio of fluorescent imaging agents and labels in North America.
VisEn's proprietary imaging agents and labels are designed to provide a range of biologically specific imaging readouts in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging disease-associated biologic targets, processes, and pathways in vivo, with several more new agents expected for launch in 2009.
Applications of the VisEn agents include imaging disease progression and therapeutic response in real time in oncology, inflammation, cardiovascular disease, bone disease, and pulmonary diseases, all in the context of the living animal. VisEn also offers specialized in vivo agent labeling platforms, including its proprietary VivoTag fluorescence labeling dyes for custom in vivo agent development, and its NanoSpark in vivo labeling nanoparticles.
VisEn's agents and labels are designed to be compatible with a range of fluorescence imaging systems, including the CRi Maestro system.